Avidity Biosciences RNA 深 滬
已收盤 02-06 16:00:00 美东时间
72.90
+0.080
+0.11%
華盛通- 最 高72.95
- 今 開72.92
- 成交量 328.30万股
- 最 低 72.785
- 昨 收 72.82
- 總市值 112.62亿
- 52周最高 73.06
- 市盈率 靜 --
- 換手率 2.13%
- 52周最低 21.51
- 委 比 77.70%
- 總股本 1.54亿
- 歷史最高 73.06
- 量 比 1.18
- 振 幅 0.23%
- 歷史最低 4.825
- 每 手 1
- 風險率 17.29%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Avidity Plans Spin-Off Amid Novartis Acquisition Agreement
The latest update is out from Avidity Biosciences ( ($RNA) ). On February 2, 20...
02-04 06:47
Avidity Biosciences Announces Expected Record Date for Spin-Off
SAN DIEGO, Feb. 2, 2026 /PRNewswire/ -- Avidity Biosciences, Inc. ("Avidity") (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibo...
02-03 10:44
Avidity Biosciences Chief Medical Officer Steven George Hughes Reports Disposal of Common Shares
Avidity Biosciences Chief Medical Officer Steven George Hughes Reports Disposal of Common Shares Steven George Hughes, Chief Medical Officer of Avidity Biosciences Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This
01-24 06:34
Avidity Biosciences Chief Scientific Officer Michael Flanagan Reports Disposal of Common Shares
Avidity Biosciences Chief Scientific Officer Michael Flanagan Reports Disposal of Common Shares W. Michael Flanagan, Chief Scientific Officer of Avidity Biosciences Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This
01-24 06:34
Avidity Biosciences CEO Sarah Boyce Reports Disposal of Common Shares
Avidity Biosciences CEO Sarah Boyce Reports Disposal of Common Shares Sarah Boyce, President and CEO of Avidity Biosciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologie
01-24 06:34
Avidity Biosciences CFO Michael F. MacLean Reports Disposal of Common Shares
Avidity Biosciences CFO Michael F. MacLean Reports Disposal of Common Shares Michael F. MacLean, Chief Financial Officer of Avidity Biosciences Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was creat
01-24 06:34
Avidity Biosciences Chief Human Resources Officer Teresa McCarthy Reports Disposal of Common Shares
Avidity Biosciences Chief Human Resources Officer Teresa McCarthy Reports Disposal of Common Shares Teresa McCarthy, Chief Human Resources Officer of Avidity Biosciences Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: Thi
01-24 06:34
Dyne upgraded at Oppenheimer on upcoming trial readout from Avidity
Oppenheimer upgraded Dyne Therapeutics (DYN) on Wednesday, citing a positive read-through from data that Novartis’ (NVS) buyout target Avidity Biosciences (RNA) is set to release this year from a late...
2025-12-11 02:43
诺华宣布收购Avidity Biosciences
诺华近日宣布达成一项协议，将收购Avidity Biosciences, Inc.，这是一家位于圣地亚哥的生物制药公司、专注于开发一种能将RNA递送至肌肉的新型...
2025-11-25 17:44
Avidity Biosciences Announces MAP For Investigational Therapy Delpacibart Zotadirsen For Eligible People With Duchenne Muscular Dystrophy Mutations Amenable To Exon 44 Skipping In US
Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced its Managed Access
2025-11-19 22:15
